MoonLake Immunotherapeutics Quarterly Income Statement
NASDAQ: MLTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
10.82+0.24 (+2.27%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MoonLake Immunotherapeutics revenue and earnings
MoonLake Immunotherapeutics reported a net loss of $61.8 million, compared with a loss of $55.2 million a year earlier. Diluted earnings per share came in at -$0.84.
Summary generated from market data by MetaCap's automated system. Methodology
MoonLake Immunotherapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 61.66M | 70.02M | 65.22M | 71.43M | 60.70M | 47.48M | 49.58M | 43.11M | 30.58M | 19.82M | 15.03M | 12.98M |
| Research & Development | 50.22M | 54.52M | 56.01M | 60.63M | 49.76M | 36.46M | 40.36M | 35.74M | 23.66M | 13.01M | 8.10M | 7.59M |
| Operating Income | -61.66M | -70.02M | -65.22M | -71.43M | -60.70M | -47.48M | -49.58M | -43.11M | -30.58M | -19.82M | -15.03M | -12.98M |
| Interest Expense | 2.63M | 2.27M | 1.99M | 3.20M | 2.04M | 18.00K | 0 | 0 | 0 | 0 | — | — |
| Other Income (Expense) | 2.58M | 3.21M | 4.44M | 4.05M | 6.78M | 7.10M | 3.23M | 7.09M | 5.90M | 5.92M | 7.19M | 1.39M |
| Income Tax | 90.00K | 622.00K | 248.00K | 115.00K | 95.00K | 153.00K | 41.00K | 92.00K | 79.00K | 70.00K | 43.92K | 28.92K |
| Net Income | -61.80M | -69.71M | -62.43M | -69.73M | -55.22M | -39.94M | -45.60M | -35.39M | -24.27M | -13.67M | -7.44M | -9.43M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.84 | -0.98 | -0.93 | -1.10 | -0.87 | -0.63 | -0.72 | -0.56 | -0.39 | -0.22 | -0.09 | -0.18 |
| EPS (Diluted) | -0.84 | -0.98 | -0.93 | -1.10 | -0.87 | -0.63 | -0.72 | -0.56 | -0.39 | -0.22 | -0.09 | -0.18 |
| Shares Outstanding (Basic) | 73.92M | 71.27M | — | 63.37M | 63.28M | 63.23M | — | 62.90M | 62.87M | 62.64M | — | 53.52M |
| Shares Outstanding (Diluted) | 73.92M | 71.27M | — | 63.37M | 63.28M | 63.23M | — | 62.90M | 62.87M | 62.64M | — | 53.52M |
| EBITDA | -60.76M | -69.18M | -64.47M | -70.69M | -59.96M | -47.11M | -49.22M | -42.76M | -30.24M | -19.49M | -15.03M | -12.97M |
This table shows 12 quarterly periods of MoonLake Immunotherapeutics's income statement, from Q2 2026 back to Q3 2023, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow MLTX's reporting calendar. What is a income statement?